
EKSO Stock Forecast & Price Target
EKSO Analyst Ratings
Bulls say
Ekso Bionics Holdings Inc. is poised for significant revenue growth, with a projection of $23 million for 2025, primarily driven by increased placement of EksoNR devices following a strong quarterly performance that demonstrated 21%-24% quarter-over-quarter growth. The potential scaling of revenue from the Indego Personal segment, contingent on successful navigation of initial claims and reimbursement strategies, highlights a promising long-term growth outlook. Additionally, the company's strategic partnerships and anticipated demand in key regional markets, particularly Europe, underscore opportunities for expanding its market presence and enhancing overall value.
Bears say
Ekso Bionics Holdings Inc reported total revenue of $17.9 million in 2024, representing a 2% year-over-year decline from the previous year's record revenue of $18.3 million, primarily due to reduced enterprise sales linked to procurement cycle fluctuations in integrated delivery networks. Despite some revenue growth in Europe, especially in France, the overall decline highlights vulnerability in the company's sales performance in its core markets. Additionally, the reported loss on the revaluation of warrant liabilities suggests potential financial instability, contributing to a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.
EKSO Analyst Forecast & Price Prediction
Start investing in EKSO
Order type
Buy in
Order amount
Est. shares
0 shares